PIA
PTLA

Piedmont Investment Advisors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Piedmont Investment Advisors’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,131
Closed -$43K – 2730
2018
Q2 		$43K Buy
+1,131
New +$43.3K ﹤0.01% 1352

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Piedmont Investment Advisors's PTLA Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2018, closing a stake of 1,131 shares — an estimated $43K sold.

Piedmont Investment Advisors first reported a position in PTLA in Q2 2018 and held it in 1 quarter. The position peaked at $43K in Q2 2018. 197 funds tracked by Wall St. Rank hold PTLA as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 1,131 Portola Pharmaceuticals, Inc. shares in Q3 2018, an estimated $43K.
  • Piedmont Investment Advisors first reported a position in Portola Pharmaceuticals, Inc. in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Portola Pharmaceuticals, Inc. position peaked at $43K in Q2 2018.
  • 197 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.